Inform, Empower, Connect

ICONIC: Improving Outcomes Through Collaboration in OsteosarComa

Last Update Posted : 2023-06-09

The aim of the trial

  • This study aims to collect detailed information from osteosarcoma patients across all ages to better understand how and why osteosarcoma occurs. Information will include the size of the disease, how and where it was diagnosed, what treatments were given and the response to treatment. Patients will be required to give blood and tissue samples to be analyzed for research. The patient information and the results from the sample analysis will help answer why osteosarcoma occurs, grows, spreads and why some people respond better to treatment than others. This information can be used to later develop new treatments for osteosarcoma and help improve the care and support for those affectedby osteosarcoma. This study is observation based with no additional treatment given other than usualtreatment given as standard care.
United Kingdom,
London, Aberdeen, Birmingham, Cambridge, Cardiff, Glasgow, Leicester, Liverpool, Manchester, Newcastle, Nottingham, Oswestry, Oxford, Sheffield,
Trial Type
Trial Phase
Trial Status
Minimum age
Maximum age
Key Contact
-Krystyna Reczko, Rubina Begum, 020 7679 9878, 020 7679 9514,,
Clinical Trial ID

Key Information

  • This study only involves patient observation and doesn’t provide a new treatment for osteosarcoma. Treatment for osteosarcoma hasn’t changed with little improvement in the outcome for patients in over 20 years. Clinicians can use this essential research to develop new treatments and improve the outcome for osteosarcoma patients. Patients must have been diagnosed in the UK less than four months before registration to be eligible for this study.

How the treatment works

  • No treatments are given in this clinical trial.
  • Visit our drugs and interventions page to find out more about this treatment, including how it works and what it’s used for.

Who is the trial for?

  • The below points are a summary of who can enter the trial.
  • People with a new diagnosis of osteosarcoma.

Who is the trial not for?

  • The below points are a summary of who can’t enter the trial.
  • People who were diagnosed more than four months before registering for the study.


  • ONTEX is intended to supplement, not replace, your healthcare team. Patients should always discuss a clinical trial with their healthcare team. If a patient is eligible for a trial the trial team will be able to provide more in-depth information about the trial so the patient can make an informed decision before taking part. Trial information has been sourced from The content is then reviewed weekly by the Osteosarcoma Now team. All the trials also have a patient-friendly summary and key information section written by the team at Osteosarcoma Now. We have also included a description of the medications being used in the trial and summarised the inclusion and exclusion criteria in the ‘who is this trial (not) for’ sections. To the best of our knowledge the clinical trial database is up-to-date and accurate.However, we cannot assume any liability for the accuracy or completeness of the information.